circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X 21st Annual H. C. Wainwright Global Investment Conference
    Sep 10, 2019 1:20 PM EDT

    21st Annual H. C. Wainwright Global Investment Conference
    Sep 10, 2019 1:20 PM EDT
  • Webcast
    X 17th Annual Morgan Stanley Global Healthcare Conference
    Sep 9, 2019 8:10 AM EDT

    17th Annual Morgan Stanley Global Healthcare Conference
    Sep 9, 2019 8:10 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings Planned Phase 2 Clinical Trial Design  Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019 SOUTH SAN FRANCISCO, Calif., Sept.
Toggle Summary Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23 rd Annual Heart Failure Society of America (HFSA) Scientific Meeting in Philadelphia . The posters will be presented on September 13, 2019
Toggle Summary Cytokinetics to Present at September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: 17 th Annual Morgan Stanley
Toggle Summary Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA).

EVENTS

There are currently no events to display.